Critical Reviews in Oncology HematologyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7

349 records returned

EditorialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We have previously published two parts of this mini series on imagery techniques; this is now the third and final part. Recent developments in imagery techniques provide important progress in cancer diagnostic and treatment. Today, at least in oncology, images can give so much information that diagnoses are subject to less incertainty and clues are also given to optimize treatment. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - November 13, 2009 Category: Cancer & Oncology Authors: B. Desoize Tags: Imaging and Cancer - Part III Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - November 13, 2009 Category: Cancer & Oncology Source Type: journals

Identification of Raman spectroscopic markers for the characterization of normal and adenocarcinomatous colonic tissuesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Raman spectroscopy has been recognised as a valuable analytical tool in biological and medical research. This technique allows probing molecular vibrations of samples without external labels or extensive preparation. This non-destructive optical technique can provide rapid and objective and reproducible measurements of sample biochemistry and identify variations that occur between healthy and diseased tissues. In fact, biochemical changes within tissue may either initiate disease or occur as a result of the disease process. The qualitative analysis of such changes provides important clues in the search for a spec...
Source: Critical Reviews in Oncology Hematology - October 12, 2009 Category: Cancer & Oncology Authors: A. Beljebbar, O. Bouché, M.D. Diébold, P.J. Guillou, J.P. Palot, D. Eudes, M. Manfait Tags: Imaging and Cancer - Part III Source Type: journals

Guide for AuthorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 2, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 2, 2009 Category: Cancer & Oncology Source Type: journals

Volume ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 7, 2009 Category: Cancer & Oncology Source Type: journals

Subject IndexEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 7, 2009 Category: Cancer & Oncology Source Type: journals

Author IndexEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 7, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 7, 2009 Category: Cancer & Oncology Source Type: journals

Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim supportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Shortening duration of chemotherapy-induced neutropenia may reduce risk of infection and aid subsequent chemotherapy delivery. Cycle 1 neutrophil recovery was evaluated in 59 elderly women with breast cancer receiving adjuvant FEC100 (5-fluorouracil 500mg/m2, epirubicin 100mg/m2 and cyclophosphamide 500mg/m2) and randomized to pegfilgrastim primary prophylaxis (PP) from cycle 1, or secondary prophylaxis (SP, i.e., subsequent to a neutropenic event [no G-CSF in cycle 1]). In cycle 1, grade 4 neutropenia occurred in 77% (PP; N=30) and 72% (SP; N=29). Duration of grade 3–4 neutropenia was shorter with pegfilgrasti...
Source: Critical Reviews in Oncology Hematology - July 13, 2009 Category: Cancer & Oncology Authors: W. Brugger, P. Bacon, S. Lawrinson, G. Romieu Tags: Geriatric Oncology (under the auspices of SIOG) Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - July 5, 2009 Category: Cancer & Oncology Source Type: journals

Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Aromatase inhibitors have been shown to be superior to Tamoxifen in several settings. It is unclear whether this superiority extends to their use as primary endocrine therapy in elderly patients with early operable primary breast cancer. Biological characteristics of the tumours may aid in selecting the most suitable agent.Primary endocrine therapy with Anastrozole in 64 women >70 years with oestrogen receptor α-positive (ERα+) breast cancer was compared to that in 84 treated with Tamoxifen during the same period. Biomarkers were assessed by immunohistochemistry on diagnostic core biopsies.There was no signific...
Source: Critical Reviews in Oncology Hematology - June 9, 2009 Category: Cancer & Oncology Authors: G. Okunade, A.R. Green, M. Ying, A. Agrawal, E.C. Paish, M. Aleskandrany, L. Winterbottom, K. Hassell, D.A.L. Morgan, I.O. Ellis, K.L. Cheung Tags: Geriatric Oncology (under the auspices of SIOG) Source Type: journals

Guide for AuthorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 7, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 7, 2009 Category: Cancer & Oncology Source Type: journals

ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 19, 2009 Category: Cancer & Oncology Source Type: journals

Subject IndexEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 19, 2009 Category: Cancer & Oncology Source Type: journals

Author IndexEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 19, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 19, 2009 Category: Cancer & Oncology Source Type: journals

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective surveyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Purpose: To evaluate the frequency of chemotherapy-induced myelotoxicity in cancer patients, the related treatment (G-CSF, rHuEPO), and the occurrence of chemotherapy dose reductions, delays or discontinuations.Patients and methods: We retrospectively collected data from 1175 patients who completed at least four chemotherapy courses at 64 Italian Centres.Myelotoxicity was defined as anemia (Hb (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 29, 2009 Category: Cancer & Oncology Authors: Lazzaro Repetto, On behalf of CIPOMO investigators Tags: Geriatric Oncology (under the auspices of SIOG) Source Type: journals

Rectal cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Rectal cancer is an important tumour from an epidemiological point of view and represents the benchmark for an optimal use of integrated treatments (surgery, radiotherapy and chemotherapy) in the oncological practice. The conventional use of total mesorectal excision and the integration with radiochemotherapy, better if preoperatively, are now able to increase survival, to decrease the occurrence of pelvic recurrence and to ameliorate the quality of life of patients. Updated recommendations for the management of these patients are here reported. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 21, 2009 Category: Cancer & Oncology Authors: Maria Giulia Zampino, Roberto Labianca, Giordano D. Beretta, Elena Magni, Gemma Gatta, Maria Cristina Leonardi, Antonio Chiappa, Roberto Biffi, Filippo de Braud, Jacques Wils Tags: START Chapters Source Type: journals

Pain therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Cancer-related pain is a major issue of healthcare systems worldwide. The reported incidence, considering all stages of the disease, is 51%, which can increase to 74% in the advanced and terminal stages. For advanced cancer, pain is moderate to severe in about 40–50% and very severe or excruciating in 25–30% of cases.Pain is both a sensation and an emotional experience. Pain is always subjective; and may be affected by emotional, social and spiritual components thus it has been defined as “total pain”.From a pathophysiological point of view, pain can be classified as nociceptive (somatic and visceral), ne...
Source: Critical Reviews in Oncology Hematology - April 21, 2009 Category: Cancer & Oncology Authors: Carla Ripamonti, Elena Bandieri Tags: START Chapters Source Type: journals

Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Purpose: Healthy elderly patients with metastatic colorectal cancer may benefit from chemotherapy as much as the younger population. This analysis compares the outcomes of first-line oxaliplatin plus fluoropyrimidines in elderly versus young patients.Patients and methods: 348 patients were randomized to capecitabine 1000mg/(m212h), days 1–14 plus oxaliplatin 130mg/m2 day 1, every 3 weeks or weekly infusional 5-FU 2250mg/m2 over 48h plus bimonthly oxaliplatin 85mg/m2. We evaluated response rate, time to progression, overall survival and toxicity according to age.Results: ORR for elderly and young patients were 3...
Source: Critical Reviews in Oncology Hematology - April 21, 2009 Category: Cancer & Oncology Authors: Javier Sastre, Enrique Aranda, Bartomeu Massutí, Jose Tabernero, Manuel Chaves, Albert Abad, Alfredo Carrato, Juan José Reina, Bernardo Queralt, Auxiliadora Gómez-España, Encarnación González-Flores, Fernando Rivera, Ferrán Losa, Teresa García, Pe Tags: Geriatric Oncology (under the auspices of SIOG) Source Type: journals

Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The Renal Insufficiency and Anticancer Medications (IRMA) study is a French national, observational study which demonstrated the high prevalence of abnormal renal function in a population of 4684 solid tumor patients. Among them, 50–60% had decreased renal function, and 80% were treated with anticancer drugs that either necessitated dosage adjustment in case of renal insufficiency (RI) or were potentially nephrotoxic drugs. Since elderly patients are well-known to have reduced renal function, either due to physiological aging or their disease/medication history, a subgroup analysis of this particular population...
Source: Critical Reviews in Oncology Hematology - April 21, 2009 Category: Cancer & Oncology Authors: Vincent Launay-Vacher, Jean-Philippe Spano, Nicolas Janus, Joseph Gligorov, Isabelle Ray-Coquard, Stéphane Oudard, Xavier Pourrat, Jean-François Morere, Philippe Beuzeboc, Gilbert Deray, The Renal Insufficiency and Anticancer Medications (IRMA) Study Gr Tags: Geriatric Oncology (under the auspices of SIOG) Source Type: journals

Current management of stage I testicular non-seminomatous germ cell tumoursEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Testicular germ cell tumors represent the most common malignancies in young males between the ages of 15 and 35; 50% of those with non-seminomatous germ cell tumors (NSGCT) have clinical stage I at diagnosis. Predictors for relapse include lymphovascular invasion, percentage of embryonal-cell carcinoma component, absence of yolk-sack histology and MIB1 proliferation rate.Therapeutic options following orchidectomy in stage I NSGCT comprise nerve-sparing retroperitoneal lymph node dissection (RPLND), surveillance or adjuvant cisplatin-based chemotherapy. Using a risk adapted approach, in about 50% of patients with ...
Source: Critical Reviews in Oncology Hematology - April 21, 2009 Category: Cancer & Oncology Authors: D. Pectasides, E. Pectasides, A. Constantinidou, G. Aravantinos Source Type: journals

Appraisal of immune response in lymphoproliferative syndromes: A systematic reviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: In lymphoproliferative syndromes, tumoural–immune cell interactions depend on a number of factors related to tumoural and immune cells. Recent gene expression data tend to confirm the decisive role of the reactive microenvironment in the development and clinical behaviour of lymphoproliferative syndromes, and encourage particular interest in the role of T cells and accessory cells. This systematic review brings together the accumulated knowledge about “immune signatures” in Hodgkin and non-Hodgkin lymphomas. Extracted results revealed that the presence of T lymphocytes, regulatory T cells and non-activated ...
Source: Critical Reviews in Oncology Hematology - April 21, 2009 Category: Cancer & Oncology Authors: Tomás Álvaro, Marylène Lejeune, Patricia Escrivá, Lluís E. Pons, Ramón Bosch, Joaquín Jaén, Carlos López, Maria-Teresa Salvadó, Silvia de Sanjosé Source Type: journals

Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectivesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Tumor hypoxia is a common feature of many cancers. A master regulator of hypoxic response is the transcription factor hypoxia-inducible factor-1 (HIF-1). It functions as a master regulator of oxygen and undergoes conformational changes in response to varying oxygen concentrations. In this paper, we review what has been described about HIF-1: its structure, its regulation and target genes, its role in cancer, and its implication for cancer therapy. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 21, 2009 Category: Cancer & Oncology Authors: Zaher K. Otrock, Hassan A. Hatoum, Ahmad H. Awada, Rim S. Ishak, Ali I. Shamseddine Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 21, 2009 Category: Cancer & Oncology Source Type: journals

Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical resultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Neuroendocrine tumors can originate almost everywhere in the body and consist of a great variety of subtypes. This paper focuses on molecular imaging methods using nuclear medicine techniques in neuroendocrine tumors, coupling molecular uptake mechanisms of radiotracers with clinical results. A non-systematic review is presented on receptor based and metabolic imaging methods. Receptor-based imaging covers the molecular backgrounds of somatostatin, vaso-intestinal peptide (VIP), bombesin and cholecystokinin (CCK) receptors and their link with nuclear imaging. Imaging methods based on specific metabolic properties...
Source: Critical Reviews in Oncology Hematology - April 9, 2009 Category: Cancer & Oncology Authors: Klaas P. Koopmans, Oliver N. Neels, Ido P. Kema, Philip H. Elsinga, Thera P. Links, Elisabeth G.E. de Vries, Pieter L. Jager Source Type: journals

Chemotherapy options and outcomes in older adult patients with colorectal cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The majority of patients with colorectal cancer (CRC) are ≥65 years of age, yet older patients with CRC remain under-represented in clinical trials. Older adult patients may be more likely than younger patients to experience chemotherapy-related toxicities due to factors such as existing comorbidities, incompatibility of chemotherapy with other medications, and age-related reduction in the detoxification and elimination potential of the liver and kidneys. However, the older patient group are a heterogeneous population. The available data on treatment of older patients with CRC indicate that fit older adult pati...
Source: Critical Reviews in Oncology Hematology - April 7, 2009 Category: Cancer & Oncology Authors: Muhammad W. Saif, Stuart M. Lichtman Tags: Geriatric Oncology (under the auspices of SIOG) Source Type: journals

Identification and functional validation of therapeutic targets for malignant melanomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Despite remarkable effort, malignant melanoma still remains a potent killer. Millions of dollars have been spent on clinical trials that have not succeeded in achieving significant patient benefit. The thorough validation of drug targets at an earlier stage is, therefore, an essential step in the development of new therapies. Since the development of microarray experiments, putative drug targets are being identified in a high-throughput manner. Though high-throughput functional validation methods are currently being established, a more specific, pre-clinical analysis of promising target genes remains inevitable. ...
Source: Critical Reviews in Oncology Hematology - March 31, 2009 Category: Cancer & Oncology Authors: Gabriela Gremel, Mairin Rafferty, Thomas Y.K. Lau, William M. Gallagher Source Type: journals

Is age a prognostic factor for treatment outcome in renal cell cancer—A comprehensive reviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Life expectancy gradually increases in the Western part of the world. Older patients may present with small, localized tumours and/or advanced or metastatic disease and still, potentially, have a considerable life expectancy. The consequence of the increased life span is that in older patients all potential treatments have to be discussed.A critical review of the literature regarding the treatment of different stages of renal cell cancer (RCC) in the elderly patient group was conducted.Elderly people with small renal masses are up to 3.5 times more likely to have a benign lesion.The oncological outcome from nephr...
Source: Critical Reviews in Oncology Hematology - March 27, 2009 Category: Cancer & Oncology Authors: Enrique Ramos-Barcelo, Jorge Rioja, Pilar Laguna Pes, Jean J.M.C.H. de la Rosette, Theo M. de Reijke Tags: Geriatric Oncology (under the auspices of SIOG) Source Type: journals

Innovative biomarkers for prostate cancer early diagnosis and progression.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The marker currently used for prostate cancer (CaP) detection is an increase in serum prostate-specific antigen (PSA). However, the PSA test which may give false positive or negative information, is not reliable and does not allow the differentiation of benign prostate hyperplasia (BPH), non-aggressive CaP and aggressive CaP. There is thus an urgent need to search for novel CaP biomarkers to improve the early detection and accuracy of diagnosis, determine the aggressiveness of CaP and to monitor the efficacy of treatment. Proteomic techniques allow for a high-throughput analysis of bio-fluids with the visualization and...
Source: Critical Reviews in Oncology Hematology - March 26, 2009 Category: Cancer & Oncology Authors: You J, Cozzi P, Walsh B, Willcox M, Kearsley J, Russell P, Li Y Tags: Crit Rev Oncol Hematol Source Type: journals

Identification and functional validation of therapeutic targets for malignant melanoma.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite remarkable effort, malignant melanoma still remains a potent killer. Millions of dollars have been spent on clinical trials that have not succeeded in achieving significant patient benefit. The thorough validation of drug targets at an earlier stage is, therefore, an essential step in the development of new therapies. Since the development of microarray experiments, putative drug targets are being identified in a high-throughput manner. Though high-throughput functional validation methods are currently being established, a more specific, pre-clinical analysis of promising target genes remains inevitable. For th...
Source: Critical Reviews in Oncology Hematology - March 26, 2009 Category: Cancer & Oncology Authors: Gremel G, Rafferty M, Lau TY, Gallagher WM Tags: Crit Rev Oncol Hematol Source Type: journals

Is age a prognostic factor for treatment outcome in renal cell cancer-A comprehensive review.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Life expectancy gradually increases in the Western part of the world. Older patients may present with small, localized tumours and/or advanced or metastatic disease and still, potentially, have a considerable life expectancy. The consequence of the increased life span is that in older patients all potential treatments have to be discussed. A critical review of the literature regarding the treatment of different stages of renal cell cancer (RCC) in the elderly patient group was conducted. Elderly people with small renal masses are up to 3.5 times more likely to have a benign lesion. The oncological outcome from nephron ...
Source: Critical Reviews in Oncology Hematology - March 25, 2009 Category: Cancer & Oncology Authors: Ramos-Barcelo E, Rioja J, Pes PL, de la Rosette JJ, de Reijke TM Tags: Crit Rev Oncol Hematol Source Type: journals

Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Bone is the most common site of metastatic spread in breast cancer patients. The use of bisphosphonates (BPs) in women with bone metastases from breast cancer has been shown to reduce the incidence, and delay the onset of, skeletal-related events. Indeed, BPs are now an established standard of care in treating patients with bone metastases. As with many new therapies, once efficacy in the metastatic setting is demonstrated, therapies are tested in the adjuvant setting. There are a number of trials that have tested the hypothesis that BP therapy in women with early breast cancer may not only reduce the development...
Source: Critical Reviews in Oncology Hematology - March 23, 2009 Category: Cancer & Oncology Authors: Orit C. Freedman, Eitan Amir, Mark J. Clemons Source Type: journals

Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bone is the most common site of metastatic spread in breast cancer patients. The use of bisphosphonates (BPs) in women with bone metastases from breast cancer has been shown to reduce the incidence, and delay the onset of, skeletal-related events. Indeed, BPs are now an established standard of care in treating patients with bone metastases. As with many new therapies, once efficacy in the metastatic setting is demonstrated, therapies are tested in the adjuvant setting. There are a number of trials that have tested the hypothesis that BP therapy in women with early breast cancer may not only reduce the development of sk...
Source: Critical Reviews in Oncology Hematology - March 21, 2009 Category: Cancer & Oncology Authors: Freedman OC, Amir E, Clemons MJ Tags: Crit Rev Oncol Hematol Source Type: journals

Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Medulloblastoma and supratentorial primitive neuroectodermal tumors are rare diseases in adults. Due to this rarity, few prospective clinical trials have been conducted on medulloblastoma in adults, investigations being based exclusively on retrospective studies; the populations considered in literature are small, and the different treatments given span decades, during which diagnostic procedures, neurosurgical skills and radiotherapy techniques have changed. Unlike pediatric patients, adult medulloblastoma patients have been treated according to risk-adapted therapeutic strategies in only a few series and despit...
Source: Critical Reviews in Oncology Hematology - March 20, 2009 Category: Cancer & Oncology Authors: Alba A. Brandes, Enrico Franceschi, Alicia Tosoni, Michele Reni, Gemma Gatta, Charles Vecht, Rolf D. Kortmann Tags: START Chapters Source Type: journals

Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Medulloblastoma and supratentorial primitive neuroectodermal tumors are rare diseases in adults. Due to this rarity, few prospective clinical trials have been conducted on medulloblastoma in adults, investigations being based exclusively on retrospective studies; the populations considered in literature are small, and the different treatments given span decades, during which diagnostic procedures, neurosurgical skills and radiotherapy techniques have changed. Unlike pediatric patients, adult medulloblastoma patients have been treated according to risk-adapted therapeutic strategies in only a few series and despite risk...
Source: Critical Reviews in Oncology Hematology - March 18, 2009 Category: Cancer & Oncology Authors: Brandes AA, Franceschi E, Tosoni A, Reni M, Gatta G, Vecht C, Kortmann RD Tags: Crit Rev Oncol Hematol Source Type: journals

Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Better compliance and persistence with therapy are associated with improved patient outcomes. As more and more patients survive breast cancer, compliance with adjuvant therapy becomes increasingly important. In clinical trials, compliance with adjuvant endocrine therapy among women with breast cancer is usually high. Retrospective analyses of databases and medical records from clinical practice, insurance databases of prescription refills, and survey data show a significant decrease in persistence after 12 months of therapy. With ongoing therapy, a further decline in persistence of up to 50% has been reported. A consis...
Source: Critical Reviews in Oncology Hematology - March 17, 2009 Category: Cancer & Oncology Authors: Hadji P Tags: Crit Rev Oncol Hematol Source Type: journals

Tumors that look for their springtime in APRILEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Inflammatory cells produce a proliferation inducing ligand (APRIL), one of the most recently cloned members of the tumor necrosis factor (TNF) family. Early experiments implicated APRIL as a promoting factor in the natural course of various cancers, reinforcing the concept that host inflammatory reactions are part of a tumor development. Recent studies have further analyzed the tumor-promoting role of APRIL in patients with solid tumors or with hematological malignancies. Here, we will review the recent literature, and provide evidence that APRIL may be a useful prognostic tool and a potential target in the treat...
Source: Critical Reviews in Oncology Hematology - March 16, 2009 Category: Cancer & Oncology Authors: E. Roosnek, M. Burjanadze, P.Y. Dietrich, T. Matthes, J. Passweg, B. Huard Source Type: journals

Tumors that look for their springtime in APRIL.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inflammatory cells produce a proliferation inducing ligand (APRIL), one of the most recently cloned members of the tumor necrosis factor (TNF) family. Early experiments implicated APRIL as a promoting factor in the natural course of various cancers, reinforcing the concept that host inflammatory reactions are part of a tumor development. Recent studies have further analyzed the tumor-promoting role of APRIL in patients with solid tumors or with hematological malignancies. Here, we will review the recent literature, and provide evidence that APRIL may be a useful prognostic tool and a potential target in the treatment o...
Source: Critical Reviews in Oncology Hematology - March 13, 2009 Category: Cancer & Oncology Authors: Roosnek E, Burjanadze M, Dietrich PY, Matthes T, Passweg J, Huard B Tags: Crit Rev Oncol Hematol Source Type: journals

Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectivesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Gastroenteropancreatic endocrine tumours (GEP ETs) represent a relatively rare and heterogeneous group of neoplasms whose therapy can be challenging. The poorly differentiated, fast-growing cases are treated with chemotherapy. In the slow-growing ones, biotherapy is usually performed. Several categories of targeted therapies have been studied for their treatment in vitro and in vivo. A critical review of molecular alterations suggests a rationale for targeting angiogenesis, and the phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Accordingly, antiangiogenic agents and mTOR in...
Source: Critical Reviews in Oncology Hematology - March 2, 2009 Category: Cancer & Oncology Authors: Gabriele Capurso, Nicola Fazio, Stefano Festa, Francesco Panzuto, Filippo De Braud, Gianfranco Delle Fave Source Type: journals

Gene expression profiling and prediction of clinical outcome in ovarian cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Epithelial ovarian cancer is the most lethal gynaecological cancer. Despite debulking surgery and platinum/taxane-based chemotherapy, the prognosis remains poor with ∼25% 5-year survival. Current histo-clinical prognostic factors are insufficient to capture the complex cascade of events that drive the heterogeneous clinical behaviour of the disease. There is a crucial need to identify new prognostic subclasses of disease as well as new therapeutic targets. Today, DNA microarrays allow the simultaneous and quantitative analysis of the mRNA expression levels of thousands of genes in a tumour sample. They have bee...
Source: Critical Reviews in Oncology Hematology - March 2, 2009 Category: Cancer & Oncology Authors: Renaud Sabatier, Pascal Finetti, Nathalie Cervera, Daniel Birnbaum, François Bertucci Source Type: journals

Second and third line treatment in non-small cell lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide, and the advances in second and third line treatment have led to prognostic improvements in the latest years.Besides the two cytotoxic agents, docetaxel and pemetrexed, approved in NSCLC second line treatment, a new class of drugs against specific molecular targets seems to be an alternative to conventional treatment.Many trials are ongoing to assess the activity of new drugs, alone or in association, and new combinations of third-generation chemotherapeutic agents. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 2, 2009 Category: Cancer & Oncology Authors: Adolfo Favaretto, Giulia Pasello, Cristina Magro, Clorinda Schettino, Cesare Gridelli Source Type: journals

Gene expression profiling and prediction of clinical outcome in ovarian cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Epithelial ovarian cancer is the most lethal gynaecological cancer. Despite debulking surgery and platinum/taxane-based chemotherapy, the prognosis remains poor with approximately 25% 5-year survival. Current histo-clinical prognostic factors are insufficient to capture the complex cascade of events that drive the heterogeneous clinical behaviour of the disease. There is a crucial need to identify new prognostic subclasses of disease as well as new therapeutic targets. Today, DNA microarrays allow the simultaneous and quantitative analysis of the mRNA expression levels of thousands of genes in a tumour sample. They hav...
Source: Critical Reviews in Oncology Hematology - February 25, 2009 Category: Cancer & Oncology Authors: Sabatier R, Finetti P, Cervera N, Birnbaum D, Bertucci F Tags: Crit Rev Oncol Hematol Source Type: journals

Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Gastroenteropancreatic endocrine tumours (GEP ETs) represent a relatively rare and heterogeneous group of neoplasms whose therapy can be challenging. The poorly differentiated, fast-growing cases are treated with chemotherapy. In the slow-growing ones, biotherapy is usually performed. Several categories of targeted therapies have been studied for their treatment in vitro and in vivo. A critical review of molecular alterations suggests a rationale for targeting angiogenesis, and the phosphatidylinositol 3 kinase (PI(3)K)/AKT/mammalian target of rapamycin (mTOR) pathway. Accordingly, antiangiogenic agents and mTOR inhibi...
Source: Critical Reviews in Oncology Hematology - February 25, 2009 Category: Cancer & Oncology Authors: Capurso G, Fazio N, Festa S, Panzuto F, De Braud F, Delle Fave G Tags: Crit Rev Oncol Hematol Source Type: journals

Second and third line treatment in non-small cell lung cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide, and the advances in second and third line treatment have led to prognostic improvements in the latest years. Besides the two cytotoxic agents, docetaxel and pemetrexed, approved in NSCLC second line treatment, a new class of drugs against specific molecular targets seems to be an alternative to conventional treatment. Many trials are ongoing to assess the activity of new drugs, alone or in association, and new combinations of third-generation chemotherapeutic agents. PMID: 19249227 [PubMed - as supplied by publisher] (Source...
Source: Critical Reviews in Oncology Hematology - February 25, 2009 Category: Cancer & Oncology Authors: Favaretto A, Pasello G, Magro C, Schettino C, Gridelli C Tags: Crit Rev Oncol Hematol Source Type: journals

Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibioticsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Chemotherapy-induced myelosuppression is a major complication of chemotherapy regimens used to treat solid tumors and lymphomas. Myelosuppression is frequently accompanied by neutropenic fever and other complications and threatens the ability to maintain chemotherapy dose intensity. Two prophylaxis strategies have been evaluated to mitigate the infectious complications of myelosuppression: myeloid growth factors and antibiotic. Clinical trials and meta-analyses of trial data indicate substantial benefit to these agents in selected patients. Each type of prophylaxis has advantages and disadvantages. Additional stu...
Source: Critical Reviews in Oncology Hematology - February 24, 2009 Category: Cancer & Oncology Authors: John R. Wingard, Mohamed Elmongy Source Type: journals

Molecular classification of T-cell lymphomasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: T-cell neoplasms encompass a heterogeneous group of relatively rare disease entities. This review, focused on lymphoblastic tumors (T-ALL/LBL) and nodal-based peripheral T-cell lymphomas (PTCL), summarizes recent advances in the molecular characterization of these diseases. In T-ALL/LBL, molecular subgroups delineated by gene expression profiling correlate with leukemic arrest at specific stages of normal thymocyte development and different oncogenic pathways, and seem to be of interest for prognosis prediction. Angioimmunoblastic T-cell lymphoma (AITL), one of the most common PTCL entities, comprises neoplastic ...
Source: Critical Reviews in Oncology Hematology - February 24, 2009 Category: Cancer & Oncology Authors: Laurence de Leval, Bettina Bisig, Caroline Thielen, Jacques Boniver, Philippe Gaulard Source Type: journals